Julie A. Johnson, PharmD
Julie A. Johnson, PharmD, FCCP, BCPS
Dean and Distinguished Professor
University of Florida College of Pharmacy
Department of Pharmacotherapy and Translational Research
OFFICE: HPNP 4332
|BS||Ohio State University||Pharmacy|
|PharmD||University of Texas Austin & University of Texas||Pharmacy|
|Post-Doctoral Fellowship||Ohio State University||Cardiovascular Pharmacology/Pharmacokinetics|
Julie A. Johnson, Pharm.D., is dean of the University of Florida College of Pharmacy and distinguished professor of Pharmacy and Medicine. Johnson’s research focuses on cardiovascular pharmacogenomics and genomic medicine implementation. She is an internationally-recognized leader in pharmacogenomics and genomic medicine, with over 290 peer reviewed publications and nearly $50 million in research funding as principal investigator. In 2015, 2016, 2017 she was named a Thomson Reuters (now Clarivate Analytics) Highly Cited Scientist in Pharmacology and Toxicology, and in 2018 in the Cross Discipline category, indicating she is in the top 1% of the most highly cited scientists in the field globally.
Johnson has served on the Nonprescription Drugs Advisory Committee of the FDA, the XNDA Study Section at NIH, and in numerous scientific capacities with NIH’s NHLBI. She has had leadership roles in the American College of Clinical Pharmacy (ACCP), the American Heart Association (AHA), and the American Society of Clinical Pharmacology and Therapeutics (ASCPT), for which she completed her term as President in 2017. She is an elected fellow of the ACCP, the AHA and the American College of Clinical Pharmacology (ACCP-Pharmacology). Johnson was elected to the National Academy of Medicine (formerly Institute of Medicine) in 2014 and has received numerous other awards including teaching awards from both the University of Tennessee (1996) and the University of Florida (2001); the Ohio State University Alumni Association William Oxley Thompson Award for early career achievement (1997), Leon I Goldberg Young Investigator Award from the ASCPT (2004), Paul Dawson Biotechnology Research Award, American Association of Colleges of Pharmacy (AACP) (2007), Therapeutic Frontiers Award (2009) and Russell R Miller Award for Contributions to the Literature (2010), both from ACCP, the Southeastern Universities Research Association Distinguished Scientist Award (2015); AACP Volwiler Research Achievement Award (2016), the ACCP-Pharmacology Distinguished Scientist Award (2019), and ACCP Paul Parker Medal (2019), among others.
Johnson’s research focus is cardiovascular drug pharmacogenomics, and disease-gene associations that may be relevant to pharmacogenomics, and the influence of race/ethnicity on drug response and pharmacogenomics. The majority of her research centers around efforts in hypertension, heart failure, with a primary focus on proteins that are drug targets and the impact of their genetic polymorphisms on drug response and disease. Her research has been continuously funded by the National Institutes of Health or the American Heart Association since 1990. She is a member of the NIH Pharmacogenetics Research Network, with a project focused on pharmacogenomics of antihypertensive drugs.
- Limdi NA, Cavallari LH, Lee CR, Hillegass WB, Holmes AM, Skaar TC, Pisu M, Dillon C, Beitelshees AL, Empey PE, Duarte JD, Diaby V, Gong Y, Johnson JA, Graves J, Garbett S, Zhou Z, Peterson JF; Implementing GeNomics In pracTicE (IGNITE) Network Pharmacogenetic Working Group (IGNITE-PGx). Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. Pharmacogenomics J. 2020 Feb 11. doi: 10.1038/s41397-020-0162-5.
- Cicali EJ, Smith DM, Duong BQ, Kovar LG, Cavallari LH, Johnson JA. A Scoping Review of the Evidence Behind Cytochrome P450 2D6 Isoenzyme Inhibitor Classifications. Clin Pharmacol Ther. 2020 Jan 7. doi: 10.1002/cpt.1768.
- Mehanna M, Wang Z, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Schwartz GL, Bailey KR, Johnson JA, Turner ST, Cooper-Dehoff RM. Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence. Am J Hypertens. 2020 Feb 22;33(2):e2.
- Magvanjav O, Cooper-Dehoff RM, McDonough CW, Gong Y, Hogan WR, Johnson JA. Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting. Am J Hypertens. 2020 Apr 1;33(4):316-24.
- El Rouby N, Alrwisan A, Langaee T, Lipori G, Angiolillo DJ, Franchi F, Riva A, Elsey A, Johnson JA, Cavallari LH, Winterstein AG. Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention. Clin Transl Sci. 2019 Nov 23. doi: 10.1111/cts.12729.
- Singh S, McDonough CW, Gong Y, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response. Sci Rep. 2019 Nov 21;9(1):17323.
- Shahin MH, Abdel-Rahman S, Hartman D, Johnson JA, Mitchell DY, Reynolds KS, Wagner JA, Morrissey KM. The Patient-Centered Future of Clinical Pharmacology. Clin Pharmacol Ther. 2020 Jan;107(1):72-75. doi: 10.1002/cpt.1681.
- Brouwer KLR, Schmidt S, Floren LC, Johnson JA. Clinical Pharmacology Education – The Decade Ahead. Clin Pharmacol Ther. 2020 Jan;107(1):37-39. doi: 10.1002/cpt.1652.
- Cunningham PN, Wang Z, Grove ML, Cooper-DeHoff RM, Beitelshees AL, Gong Y, Gums JG, Johnson JA, Turner ST, Boerwinkle E, Chapman AB. Hypertensive APOL1 Risk Allele Carriers Demonstrate Greater Blood Pressure Reduction with Angiotensin Receptor Blockade Compared to Low Risk Carriers. PLoS One. 2019 Sep 18;14(9):e0221957.
- Singh S, Warren HR, Hiltunen TP, McDonough CW, El Rouby N, Salvi E, Wang T, Garofalidou T, Fyhrquist F, Kontula KK, Glorioso V, Zaninello R, Glorioso N, Pepine CJ, Munroe PB, Turner ST, Chapman AB, Boerwinkle E, Johnson JA, Gong Y, Cooper-DeHoff RM. Genome wide meta-analysis of blood pressure (BP) response to β1-blockers: Results from ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies). J Am Heart Assoc. 2019 Aug;8(16):e013115.
- Cavallari LH, Johnson JA. A case for genotype-guided pain management. Pharmacogenomics. 2019 Jul;20(10):705-708. doi: 10.2217/pgs-2019-0068.
- Iniesta R, Campbell D, Venturini C, Faconti L, Singh S, Irvin MR, Cooper-DeHoff RM, Johnson JA, Turner ST, Arnett DK, Weale ME, Warren H, Munroe PB, Cruickshank K, Padmanabhan S, Lewis C, Chowienczyk P. Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals. Hypertension. 2019 Sep;74(3):614-22.
- Shahin MH, El Rouby N, Conrado DJ, Gonzalez D, Gong Y, Lobmeyer MT, Beitelshees AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Pepine CJ, Cooper-DeHoff RM, Johnson JA. β2-adrenergic receptor gene affects the heart rate response of β-blockers: evidence from 3 clinical studies. J Clin Pharmacol. 2019 Nov;59(11):1462–70.
- Cicali EJ, Weitzel KW, Elsey AR, Orlando FA, Vinson M, Mosley S, Smith DM, Davis R, Drum L, Estores D, Franciosi JP, Hagen MG, Jerkins GJ, Mercado ES, Nainaparampil J, Padron A, Rosenberg EI, Wright A, Schmidt SO, Mathews CA, Cavallari LH, Johnson JA. Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings. Genet Med. 2019 Oct;21(10):2264-2274.
- Singh S, El Rouby N, McDonough CW, Gong Y, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. Genomic association analysis reveals variants associated with blood pressure response to beta-blockers in European Americans. Clin Transl Sci. 2019 Sep;12(5):497-504.
Full Publication List via PubMed
Please click here for a list of Julie Johnson’s industry relationships.